Core Viewpoint - The company has reached a settlement with Medytox regarding the arbitration case, which will positively impact its financial statements through the distribution of remaining assets from the joint venture Medybloom Limited [1][3][6]. Arbitration Background - The arbitration was initiated by Gentix Limited (the company's wholly-owned subsidiary) against Medytox on January 18, 2023, due to the inability to achieve the cooperation objectives outlined in the joint venture agreement [2][4]. - The joint venture, Medybloom Limited, was established in 2015 to develop and sell specific medical beauty products in mainland China [1][2]. Settlement Details - The settlement agreement was signed on October 29, 2025, terminating the arbitration proceedings and allowing both parties to withdraw all related claims within ten days [6]. - A memorandum of understanding was also signed to explore further cooperation opportunities in the future [6]. Financial Impact - The company expects to recover approximately HKD 9.6 million from the remaining asset distribution, which will have a positive effect on its current financial results [6].